Typewriter Therapeutics develops mRNA-based gene therapies using a gene writing platform for site-specific insertion of therapeutic genes.
Typewriter Therapeutics has raised $56.3M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Typewriter Therapeutics's investors include RA Capital Management, ANRI, AN Ventures, Gemseki, SBI US Gateway Fund.
Typewriter Therapeutics is headquartered in Cambridge, United States.
Typewriter Therapeutics develops mRNA-based gene therapies using a gene writing platform for site-specific insertion of therapeutic genes.
Typewriter Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Typewriter Therapeutics — Funding & Investors." VCBacked, September 2, 2026, https://www.vcbacked.co/company/typewriter-therapeutics. Accessed October 2, 2026.
VCBacked. (2026). Typewriter Therapeutics — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/typewriter-therapeutics
{{cite web |title=Typewriter Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/typewriter-therapeutics |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated